Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 09/26 10:00:17 pm
55.48 USD   -1.77%
09/26BRISTOL-MYERS S : Attractive price levels
09/22 BRISTOL MYERS S : to Take Part in Leerink Partners Immuno-Oncology R..
09/20 BRISTOL MYERS S : European Medicines Agency Validates Bristol-Myers ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Bristol Myers Squibb : to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/22/2016 | 03:43pm CEST

Bristol-Myers Squibb Company (NYSE:BMY) will take part in Leerink Partners Immuno-Oncology Roundtable Conference on Thursday, September 29, 2016, in New York. Fouad Namouni, senior vice president, Head of Oncology, will answer questions about the company at 3:00 p.m. EDT.

Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedInTwitter, YouTube and Facebook.


© Business Wire 2016
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
09/22 BRISTOL MYERS SQUIBB : to Take Part in Leerink Partners Immuno-Oncology Roundtab..
09/22 BRISTOL MYERS SQUIBB : FDAnews Announces -- Future-Proofing Your Clinical Trial ..
09/20 BRISTOL MYERS SQUIBB : Awards First “Golden Tickets” for LabCentral ..
09/20 BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol-Myers Squibb&..
09/20 BRISTOL MYERS SQUIBB : Nippon Life Insurance Co Lowers stake in Bristol-Myers Sq..
09/15 BRISTOL MYERS SQUIBB : An Application for the Trademark "TOGEVDO" Has Been Filed..
09/15 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Further Understanding o..
09/15 BRISTOL MYERS SQUIBB : Reports from Bristol-Myers Squibb Advance Knowledge in Me..
09/15 FINDINGS FROM BRISTOL-MYERS SQUIBB P : Defining molecular...
09/15 BRISTOL MYERS SQUIBB : to Announce Results for Third Quarter 2016 on October 27
More news
Sector news : Pharmaceuticals - NEC
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/26 BUY ABBVIE INCORPORATED : Its Frustration Is Your Long-Term Gain
09/22 Biotech ETF IBB Could Get A Boost From A Potential Gilead Merger Or Acquisiti..
09/21 Gilead nixes clinical development of GS-5745 for ulcerative colitis
09/21 ALLERGAN : Examining The Premiums Paid
09/20 Bristol-Myers' marketing application for new use of Opdivo accepted for revie..
Advertisement
Financials ($)
Sales 2016 18 870 M
EBIT 2016 4 999 M
Net income 2016 4 395 M
Debt 2016 1 166 M
Yield 2016 2,74%
P/E ratio 2016 21,84
P/E ratio 2017 18,90
EV / Sales 2016 5,06x
EV / Sales 2017 4,60x
Capitalization 94 370 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 67,5 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-19.35%94 370
JOHNSON & JOHNSON14.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.4.21%207 809
MERCK & CO., INC.17.66%174 098
More Results